The majority of state Medicaid programs cannot afford hepatitis C medications, such as Harvoni and Sovaldi (Gilead Sciences), which can cost nearly $100,000 for a single course of treatment.

Thirty-three states spent more than $1 billion a year to treat the disease with Sovaldi, according to data released by Senators Charles Grassley (R-Iowa), and Ron Wyden (D-Ore.). That meant that only treat 2.4% of Medicaid patients who were infected with the hep C virus could be treated, according to a new report from The Fiscal Times.

This is just the latest bad news for hepatitis C drug manufacturers, including Gilead and AbbVie (which makes Technivie and Viekira Pak), after Congress recently held hearings on high drug prices and Democratic presidential candidate Hillary Clinton has made the issue a key part of her platform.

Read more..http://formularyjournal.modernmedicine.com/formulary-journal/news/more-bad-news-hep-c-drug-pricing